|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K 16/28 | |
| A61P 35/00 | |||
| A61K 39/35 |
| (11) | Patento numeris | 3102604 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15703438.0 |
| Europos patento paraiškos padavimo data | 2015-02-03 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-12-14 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-01-15 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2015/014199 |
| Data | 2015-02-03 |
| (87) | Numeris | WO 2015/119923 |
| Data | 2015-08-13 |
| (30) | Numeris | Data | Šalis |
| 201461935748 P | 2014-02-04 | US |
| (72) |
DAVIS, Craig, Bennett, US
KOEHLER, Maria, Theresa, US
YAN, Li, US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
Merck Sharp & Dohme Corp., 126 East Lincoln Avenue, Rahway, NJ 07065, US |
| (54) | COMBINATION OF A PD-1 ANTAGONIST AND A 4-1BB AGONIST FOR TREATING CANCER |
| COMBINATION OF A PD-1 ANTAGONIST AND A 4-1BB AGONIST FOR TREATING CANCER |